Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sedac Therapeutics
Loos, Hauts-de-France, France
- Ownership
- Private
- Development stage
- Other
01
Overview
Sedac Therapeutics (Société d'Etude et de Développement des Antigènes Combinatoires) was a French biotechnology company specializing in the development of peptide-based immunotherapies and synthetic vaccines. A spin-off of the Institut Pasteur de Lille and the French National Centre for Scientific Research (CNRS), the company focused on targeting infectious diseases such as malaria, HIV, hepatitis C, and herpes simplex virus. Its lead program, MSP3-LSP, was a long synthetic peptide vaccine candidate for malaria that successfully completed a Phase 1 clinical trial demonstrating safety and immunogenicity. The company also pioneered peptide-protein antigen microarray technologies for diagnostic applications before exiting via a leveraged buyout (LBO).
- Therapeutic areas
- Infectious Diseases
- Modalities
- PeptidesVaccineBiologic
- Industry
- Biotech
02
Partnerships
Institut Pasteur de LilleCentre National de la Recherche ScientifiqueEuropean Malaria Vaccine Initiative
Beyond the preview
Go deeper on Sedac Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sedac Therapeutics.